Skip to content
Back to Guavy Wire
Stocks

Watson Takes on Cancer: IBM Supercomputer Partners with Memorial Sloan-Kettering

Instruments
IBM
Share

IBM's Watson Supercomputer is getting a new job at Memorial Sloan-Kettering Cancer Center in New York City. The partnership between IBM and the hospital aims to develop tools that will improve decision-making for cancer diagnosis and therapy.

The Watson supercomputer can read 200 million pages of data in just three seconds, making it an invaluable asset in the medical field. It will work hand-in-hand with doctors to provide evidence-based statistically-ranked responses to complex medical questions.

According to Dr. Martin Kohn, IBM's Chief Medical Scientist, 'Watson will not make actual decisions. It will bring information to the doctor.' The Watson version being designed for the hospital is similar to how it played 'Jeopardy', providing suggestions and strong alternatives based on patients' medical backgrounds.

Memorial Sloan-Kettering Cancer Center's Dr. Larry Norton said, 'We are going to work with the machine and teach the machine how to make medical decisions.' The hospital expects Watson to evolve over the next year as it is fed more information about oncology.

More on Stocks

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

© 2026 Guavy Inc